Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 37, 2012, Pages

  Chan, Carmel T ^a,b   Reeves, Robert E ^a,b   Geller, Ron ^a   Yaghoubi, Shahriar S ^a,b   Hoehne, Aileen ^a,b   Solow Cordero, David E ^a   Chiosis, Gabriela ^c   Massoud, Tarik F ^d   Paulmurugan, Ramasamy ^a,b   Gambhir, Sanjiv S ^a,b,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Stanford University   (United States)

Author keywords

Bioluminescence imaging; Co chaperone p23; Drug development; PET computed tomography imaging; Small molecule inhibitors

Indexed keywords

FIREFLY LUCIFERASE; FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK PROTEIN 90 BETA; HEAT SHOCK PROTEIN 90 INHIBITOR; N (5 METHYLISOXAZOL 3 YL) 2 [4 (THIOPHEN 2 YL) 6 (TRIFLUOROMETHYL)PYRIMIDIN 2 YLTHIO]ACETAMIDE; PROTEIN P23; RENILLA LUCIFERIN 2 MONOOXYGENASE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ACETAMIDES; ANIMALS; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; IMMUNOPRECIPITATION; INTRAMOLECULAR OXIDOREDUCTASES; LACTAMS, MACROCYCLIC; LEAD; LUCIFERASES, FIREFLY; LUCIFERASES, RENILLA; MICE; MICE, NUDE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN FOLDING; PROTEIN ISOFORMS; PYRAZINES; SMALL MOLECULE LIBRARIES; THIOACETAMIDE; THIOPHENES; TOMOGRAPHY, X-RAY COMPUTED; TRITIUM;

ANIMALIA; MUS; RENILLA; RENILLA LUCIFERASE;

EID: 84866272310     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205459109     Document Type: Article

References (50)

1. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl) 82:488-499.
2. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419-424.
3. Yano M, et al. (1999) Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 137:45-51.
4. Myung J-K, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G (2004) Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci 2:8.
5. Le Brazidec JY, et al. (2004) Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J Med Chem 47:3865-3873.
6. Chiosis G (2006) Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 6:1183-1191.
7. Kamal A, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410.
8. Vetcher L, et al. (2005) Rapid engineering of the geldanamycin biosynthesis pathway by Red/ET recombination and gene complementation. Appl Environ Microbiol 71(4):1829-1835.
9. Vilenchik M, et al. (2004) Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11:787-797.
10. Moulick K, et al. (2006) Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorg Med Chem Lett 16:4515-4518.
11. Llauger L, et al. (2005) Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 48:2892-2905.
12. Immormino RM, Kang Y, Chiosis G, Gewirth DT (2006) Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. J Med Chem 49:4953-4960.
13. He H, et al. (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem 49(1):381-390.
14. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N (2002) Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 10:3555-3564.
15. Chiosis G, et al. (2003) Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 3:371-376.
16. Chiosis G (2006) Targeting chaperones in transformed systems- a focus on Hsp90 and cancer. Expert Opin Ther Targets 10:37-50.
17. McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P (2006) Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem 6:1193-1203.
18. Soga S, Shiotsu Y, Akinaga S, Sharma SV (2003) Development of radicicol analogues. Curr Cancer Drug Targets 3:359-369.
19. Proisy N, et al. (2006) Inhibition of Hsp90 with synthetic macrolactones: Synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. Chem Biol 13:1203-1215.
20. Solit DB, Chiosis G (2008) Development and application of Hsp90 inhibitors. Drug Discov Today 13:38-43.
21. Biamonte MA, et al. (2010) Heat shock protein 90: Inhibitors in clinical trials. J Med Chem 53:3-17.
22. Kim YS, et al. (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479-1492.
23. Rowlands MG, et al. (2004) High-throughput screening assay for inhibitors of heatshock protein 90 ATPase activity. Anal Biochem 327:176-183.
24. Soti C, Vermes A, Haystead TA, Csermely P (2003) Comparative analysis of the ATPbinding sites of Hsp90 by nucleotide affinity cleavage: A distinct nucleotide specificity of the C-terminal ATP-binding site. Eur J Biochem 270:2421-2428.
25. Smith-Jones PM, et al. (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22(6):701-706.
26. Oude Munnink TH, et al. (2010) (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 46:678-684.
27. Ramírez V, Mejía-Vilet JM, Hernández D, Gamba G, Bobadilla NA (2008) Radicicol, a heat shock protein 90 inhibitor, reduces glomerular filtration rate. Am J Physiol Renal Physiol 295:F1044-F1051.
28. Cao X, et al. (2008) Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol 62:985-994.
29. Chang YS, Lo CW, Sun FC, Chang MD, Lai YK (2006) Differential expression of Hsp90 isoforms in geldanamycin-treated 9L cells. Biochem Biophys Res Commun 344:37-44.
30. Chan CT, et al. (2008) Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res 68:216-226.
31. Inglese J, et al. (2006) Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 103:11473-11478.
32. Solit DB, Rosen N (2006) Hsp90: A novel target for cancer therapy. Curr Top Med Chem 6:1205-1214.
33. Workman P, Powers MV (2007) Chaperoning cell death: A critical dual role for Hsp90 in small-cell lung cancer. Nat Chem Biol 3:455-457.
34. Kotliarova S, et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68:6643-6651.
35. Nair VD, Olanow CW (2008) Differential modulation of Akt/GSK-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem 283(22):15469-15478.
36. Dandekar M, Tseng JR, Gambhir SS (2007) Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 48:602-607.
37. Bhaumik S, Lewis XZ, Gambhir SS (2004) Optical imaging of Renilla luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice. J Biomed Opt 9:578-586.
38. Bhaumik S, Gambhir SS (2002) Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 99:377-382.
39. Aliaga A, et al. (2007) A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18] fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9:144-150.
40. de Geus-Oei L-F, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen WJG (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J Nucl Med 50(Suppl 1):43S-54S.
41. Wiant D, Gersh JA, Bennett M, Bourland JD (2010) Evaluation of the spatial dependence of the point spread function in 2D PET image reconstruction using LOROSEM. Med Phys 37:1169-1182.
42. Ma Q, Lu AYH (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63:437-459.
43. Zuehlke A, Johnson JL (2010) Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93:211-217.
44. Wu YP, Kita K, Suzuki N; Yu-ping Wu KKNS (2002) Involvement of human heat shock protein 90 alpha in nicotine-induced apoptosis. Int J Cancer 100:37-42.
45. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549.
46. Molnár J, et al. (2007) Effects of nontoxic heat shock protein 90 inhibitor peptide derivatives on reversal of MDR of tumor cells. In Vivo 21(2):429-433.
47. James ML, Gambhir SS (2012) A molecular imaging primer: Modalities, imaging agents, and applications. Physiol Rev 92(2):897-965.
48. Zhou V, et al. (2004) A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem 331:349-357.
49. Tseng JR, et al. (2008) Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med 49:129-134.
50. Tseng JR, et al. (2005) Reproducibility of 3?-deoxy-3?-(18)F- fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med 46:1851-1857.